Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 10/20 | 0.49 |
| ▸ | SELP | P16109 | 7/20 | 0.37 |
| ▸ | FGF2 | P09038 | 1/20 | 0.36 |
| ▸ | MDK | P21741 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11899209 | 1.00 | SELE (0.49) | SELESELPFGF2MDKTNF | |
| SCHEMBL14932017 | 0.92 | SELE (0.52) | SELESELPFGF2MDKNT5E | |
| SCHEMBL14932018 | 0.92 | SELE (0.52) | SELESELPFGF2MDKNT5E | |
| SCHEMBL11898820 | 0.92 | SELE (0.52) | SELESELPFGF2MDKNT5E | |
| SCHEMBL2010025 | 0.92 | SELE (0.58) | SELESELPFGF2MDKNT5E | |
| SCHEMBL2010024 | 0.92 | SELE (0.58) | SELESELPFGF2MDKNT5E | |
| SCHEMBL2009280 | 0.90 | SELE (0.42) | SELEPTPN1 | |
| SCHEMBL2009282 | 0.90 | SELE (0.42) | SELEPTPN1 | |
| SCHEMBL11982149 | 0.89 | SELE (0.51) | SELESELPFGF2MDK | |
| SCHEMBL11898864 | 0.88 | SELE (0.48) | SELESELPFGF2MDKNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, ENGASE, FUT5 | SELE 158/4885SELP 260/4885FGF2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.